A new study on Alzheimer’s disease has revealed the development of an experimental molecule that could slow the progression of the disease by reactivating the brain’s immune system. The study, conducted by researchers at the Miguel Hernández University (UMH) and the École Polytechnique Fédérale de Lausanne (EPFL) in Switzerland demonstrated that the molecule, named “OLE,” can restore microglia—the brain’s defense cells—to a protective state. The findings hold significant potential for a new generation of immunological approaches to treating Alzheimer’s disease.
The research team focused on the accumulation of beta-amyloid plaques, one of the fundamental biological hallmarks of Alzheimer’s disease. Under normal conditions, microglia protect nerve tissue by clearing these toxic protein aggregates. However, as the disease progresses, the function of microglia becomes impaired, and instead of clearing toxic proteins, these cells can contribute to inflammatory mechanisms that accelerate the neurodegenerative process. The study found that the OLE molecule developed in this research redirects microglia back to a “protective phenotype.”
The researchers explained that OLE is an experimental molecule derived from the PM20D1 gene and that it enhances microglia’s ability to target beta-amyloid plaques. Following treatment, it was observed that microglia surrounded the plaques, thereby limiting their direct contact with neurons. It was stated that this biological barrier effect significantly reduced the toxic impact of the plaques on nerve cells. José Vicente Sánchez Mut, one of the researchers leading the study, noted that reactivating microglia that have lost their function in Alzheimer’s disease could pave the way for new therapeutic strategies against the disease.
New Alzheimer’s Molecule May Reduce Memory Loss
The effects of the OLE molecule were first tested in genetically modified Caenorhabditis elegans (C. elegans) worm models. In these models, which produce beta-amyloid, OLE treatment was reported to reduce toxic protein aggregation and improve the organisms’ mobility. The researchers stated that these findings represent one of the first strong indications of the molecule’s neuroprotective effect.
In the second phase of the study, OLE treatment was administered for three months in Alzheimer’s model mice. Behavioral analyses conducted after treatment revealed significant improvements in the mice’s memory performance. At the same time, examinations of brain tissue showed that beta-amyloid plaque density was significantly reduced compared to the untreated control group. The findings suggest that OLE may be effective not only at the cellular level but also on cognitive functions.
Single-cell transcriptomic analyses conducted as part of the study revealed that microglia exhibited the strongest biological response to the treatment. It was determined that OLE activates molecular pathways in microglia associated with beta-amyloid clearance and restores the cells’ ability to migrate toward plaques. While similar results were obtained in cell culture experiments, data also suggest that OLE may protect not only microglia but also neurons directly.
Scientists Are Focusing on Immune-Based Treatments for Alzheimer’s
The study, whose results were published in the journal Cell Death and Disease, is considered an important step toward the future of immune system-based approaches in Alzheimer’s treatment. The researchers announced that two European patents have been granted for the OLE molecule and that advanced translational studies are planned to bring the discovery into clinical practice. According to experts, this approach could lay the foundation for a new treatment paradigm in Alzheimer’s disease that aims to restore the brain’s natural defense mechanisms to functionality, rather than merely suppressing symptoms.
